Fig. 7

ADNVs mitigate influenza pneumonia and increase the survival rate. (A-J) Schematic diagram of the experiment. C57BL/6 mice (n = 5) were intratracheally instilled with influenza A virus strain A/PR8 (10⁴ PFU/mice), followed by ADNVs administration (25 mg/kg, i.v.). 24 h later, the mice were sacrificed for alveolar lavage and sampling. (B) H&E staining of lung tissues and lung injury score. Scale bar, 200 μm; (C) Total cell counts, (D) protein concentrations, and (E) Viral loads were assessed in BALF; qPCR assay of the levels of (F) HA and NP and (G) the cytokines as indicated in lungs; Flow cytometry analysis of the ratios of (H) CD11c⁺SiglecF⁺AMs gated in CD45⁺CD11b⁻CD64⁺, (I) CD45⁺CD11b⁺F4/80⁺ macrophages, and (J) CD45⁺CD11b⁺Ly6G⁺ neutrophils. (K) Kaplan Meier survival analyses of the mice challenged with the lethal dose of A/PR8 strain (10⁸ PFU/mice) prior to ADNVs treatment or not (n = 10). Log-rank test P < 0.01. Shown are representative images and the data are expressed as the mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001